The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Viking Therapeutics' stock recently tanked after reporting clinical trial results for an oral anti-obesity candidate. The ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

Viking (NYSE: VIK) stock is down approximately 3% after the cruise line’s second-quarter earnings report. The company ...

In the second quarter, attributable net income increased by 45 percent to 1.5 billion yuan from 1.067 billion yuan in the ...

B. Riley views the selloff in shares of Viking Therapeutics (VKTX) following VK2735 oral weight loss data as overdone. The pullback indicates the ...

In this week’s edition of InnovationRx, we look at Phil Knight’s big cancer gift, Medallion’s credentialing clearinghouse, a ...

In April 2025 , Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND ...

Current health news highlights include Viking's weight-loss pill failing to meet financial expectations, European corporate ...

The latest health news covers underwhelming results from Viking's weight-loss pill, potential tax exemptions on health insurance in India, Brazil's declining chicken exports due to bird flu, U.S.